摘要
近年来,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂作为一种研发中独具潜力的新兴糖尿病口服药已成为关注热点。SGLT2是一种低亲和力的葡萄糖转运蛋白,其特异性表达于肾脏近端小管,并在肾脏对葡萄糖的重吸收作用中扮演着重要角色。因而,特异性抑制SGLT2蛋白能够减少近端小管对葡萄糖的重吸收,促进尿葡萄糖排泄,降低糖尿病患者的血糖水平,并具有较低的低血糖风险和减轻体重等一系列潜在优势。尽管这类药物目前仍在试验中,但其治疗T2DM的效果被寄予厚望,未来有可能成为服用口服降糖药或注射胰岛素患者的辅助用药。目前部分研发中的前沿药物的临床Ⅲ期试验结果将得到的风险受益比率,将最终决定此类药物在未来糖尿病治疗中的地位。
Among the novel classes of anti-diabetic oral agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors have been the subject of particular attention. SGLT2 is a low-affinity transport system that is specifically expressed in proximal renal tubule of the kidney and plays a significant role in renal glucose reabsorption. SLGT2 inhibitors block the receptor in the proximal renal tubule in the kidney, thereby prompting glucose urinary excretion. This results not only in lowering glucose levels in the plasma, but also in aiding weight loss without inducing hypoglycemia. Although this group of medicine is still under investigation, their efficacy in the treatment of type 2 diabetes mellitus is very promising, SGLT2 inhibitors would be also expected to be beneficial in combination with insulin or other OHAs. Results of ongoing phase Ⅲ clinical trials are awaited and will determine whether the risk-benefit ratio will allow approval of this new class of agent for the management of type 2 diabetes mellitus.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2011年第11期873-876,共4页
Chinese Journal of Diabetes
关键词
糖尿病
2型
钠-葡萄糖协同转运蛋白2
高血糖
Diabetes mellitus, type 2
Sodium-coupled glucose co-transporter 2 (SGLT2)
Hyperglycemia